Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02361216 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
A Phase 3 study of Actinic Keratosis, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 729
- Enrollment target
- 1
- Study location
NCT02361216 is a Phase 3 study of Actinic Keratosis that has completed, run by LEO Pharma. The registered enrollment target is 729 participants, above the 143-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (410% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02361216, a Phase 3 study of Actinic Keratosis, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 729 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the trial is to investigate efficacy and safety of ingenol mebutate gel for actinic keratosis applied to large treatment areas once daily for three consecutive days on face, scalp or chest.
Conditions Studied
Interventions
- OTHER Vehicle
- DRUG Ingenol Mebutate
Study Locations (1)
Indiana
- Laser & Skin Surgery Center of Indiana - Carmel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 729 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02361216
The ClinicalTrials.gov registry entry for NCT02361216 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 729 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 143-participant average among 16 other Actinic Keratosis trials with a reported enrollment target (410% higher). The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Actinic Keratosis appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT02361216 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT02361216 about?
NCT02361216 is a clinical study titled "Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest". The objective of the trial is to investigate efficacy and safety of ingenol mebutate gel for actinic keratosis applied to large treatment areas once daily for three consecutive days on face, scalp or chest.
What is the current status of trial NCT02361216?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 729 participants. The study started on 2015-04. Estimated completion is 2017-03.
What conditions does trial NCT02361216 study?
This clinical trial studies the following conditions: Actinic Keratosis.
What interventions are being tested in trial NCT02361216?
The interventions under investigation include: Vehicle (OTHER), Ingenol Mebutate (DRUG).
Who is sponsoring clinical trial NCT02361216?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02361216 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Actinic Keratosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp
ACTIVE NOT RECRUITING · Phase 3
-
Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities
ACTIVE NOT RECRUITING · Phase 3
-
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
COMPLETED · Phase 3
-
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
COMPLETED · Phase 3
-
A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
COMPLETED · Phase 3
-
A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.